The treatment modalities for painful diabetic peripheral neuropathy (PDPN) include antidepressants, anticonvulsants, capsaicin, membrane stabilizers and analgesics. Recent guidelines recommend pregabalin as a first line treatment for PDPN. But controversy exists about its efficacy and safety.

The main objective of the study is to determine the safety, efficacy of pregabalin treatment for PDPN. An interventional cohort study was carried out in a tertiary care teaching hospital. Subjects who satisfy the inclusion criteria were included in the study after obtaining written informed consent. A total of 52 subjects were enrolled in the study. PDPN was confirmed by means of (1) Diabetic neuropathy symptom (DNS) score of more than one point, (2) Diabetic neuropathy examination score (DNE) of more than three points, (3) Neuropathic disability score (NDS) of more than 6 points and (4) Pain of more than 50% assessed by Visual Analog Scale (VAS). The subjects received pregabalin 75mg once daily for one week followed by 75 mg twice daily for further 3 weeks based on patient’s tolerability. Pain intensity was measured by using Short-Form McGill pain questionnaire. Safety of therapy was assessed from the incidence of adverse events including physical as well as laboratory evaluations. All study subjects’s enrolled received pregabalin. Study showed that pregabalin treatment significantly reduced pain in diabetic peripheral neuropathy with mean pain score 11.52 ± 9.30 (P value 0.00). The most common adverse effects of pregabalin were dizziness, peripheral edema, and somnolence.

The study concluded that pregabalin significantly reduces pain and improve quality of life in PDPN.There was a dose-related increase in efficacy of pregabalin treatment. Moreover, there was a dose-related increase in incidence of most adverse events which are generally mild to moderate.


C. Radhakrishnan: None. A. Ut: None. S. K: None. N. Manikath: None. R.R. Cr: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at